Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment...

|By:, SA News Editor

Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment blinatumomab achieved a complete remission, with no remaining cells in blood or bone marrow. MITI says the results are particularly striking given that the majority of enrolled patients had characteristics typically associated with a dismal outlook. (PR)